Skip to main content
Premium Trial:

Request an Annual Quote

Affibody Enters Imaging Agent Research Collaboration with GE Healthcare

NEW YORK, June 19 (GenomeWeb News) - Affibody said today that it has begun a research collaboration with GE Healthcare to develop imaging agents for applications in personalized medicine. 


Affibody will provide its Affibody molecules for three disease targets defined by GE Healthcare. The Affibody molecules will be developed for targeted in vivo imaging applications, Affibody said.


GE Healthcare has the exclusive option to license the molecules for development and commercialization as imaging agents, while Affibody retains rights for use of the molecules outside the scope of in vivo diagnostic and medical imaging.

The Scan

Two J&J Doses

Johnson & Johnson says two doses of its SARS-CoV-2 vaccine provides increased protection against symptomatic COVID-19, CNN reports.

Pfizer-BioNTech Vaccine Response in Kids

The Pfizer-BioNTech SARS-CoV-2 vaccine in a lower-dose format appears to generate an immune response among children, according to the Washington Post.

Chicken Changes to Prevent Disease

The Guardian writes that researchers are looking at gene editing chickens to help prevent future pandemics.

PNAS Papers on Siberian Dog Ancestry, Insect Reproduction, Hippocampal Neurogenesis

In PNAS this week: ancestry and admixture among Siberian dogs, hormone role in fruit fly reproduction, and more.